Also, the interim analysis of results of SITAGRAMI (Safety and Efficacy of Sitagliptin plus Granulocyte Colony-Stimulating Factor in Patients Suffering from Acute Myocardial Infarction), a phase III multicenter trial testing the myocardial regenerating effects after an acute MI of the combination of sitagliptin with G-CSF, are encouraging but need to be confirmed with completion of the long-term study [38]. The gene discussed is CSF3; the disease is myocardial infarction.